MCNV, Global Initiative on Psychiatry, and World Granny
1
ME Loeb, Arne H Eide
1
MedGrave
1
Medical Protection Society
1
Medicine
1
Mediscript Ltd
1
Mediterranean Journal of Social Sciences MCSER Publishing, Rome-Italy
1
Meierhofer, R
1
Mercer, E
1
Médecins Sans Frontières (MSF)
1
Miller, C.
1
Ministeria de Saude, Brasil
1
Ministerio de Salud Publica, Santo Domingo
1
Ministerio de Salud Pública y Bienestar Social
1
Ministry of Education, Rwanda
1
Ministry of gender, labour and social development
1
Ministry of Health & Family Welfare, India
1
Ministry of Health & Ministry of Local Government, Gabarone, Botswana
1
Ministry of Health and Family Welfare & Indian Council for Medical Research
1
Ministry of Health and Family Welfare, Bangladesh
1
Ministry of Health and Family Welfare, Government of India
1
Ministry of Health and Population, Ministry of Health, Nepal
1
Ministry of Health and Sanitation, International Centre for Eye Health, Sightsavers
1
Ministry of Health and Social Services (MOHSS), UNAIDS
1
Ministry of Health and Social Welfare (MoHSS), Kingdom of Lesotho
1
Ministry of Health and Social Welfare (MoHSW), Kingdom of Lesotho
1
Ministry of Health and Social Welfare, Dar es Salaam, Ministry of Health, Zanzibar, National Bureau of Statistics, Zanzibar, Tanzania, and ICF International
1
Ministry of Health and Social Welfare, Liberia
1
Ministry of Health Ghana
1
Ministry of Health Republic of Indonesia
1
Ministry of Health Sierra Leone
1
Ministry of Health, Ghana
1
Ministry of Health, Government of Liberia
1
Ministry of Health, Liberia
1
Ministry of Health, Republic of Rwanda
1
Ministry of Health, Repulic of Uganda
1
Ministry of Health, Rwanda & Rwanda Biomedical Centre
1
Ministry of Public Health, Cameroon
1
Ministry of Rural Development
1
Mohamed Aouamri
1
Mohammed Kabir, Zubair Iliyasu, Isa S Abubakar & Muktar H Aliyu
1
MRC South Africa
1
MSF
1
MSMGF
1
Myron L Belfer, Suzan Song
1
N. Drew
1
N. G. Kiobi, S. N. Nebere, J. K. Karanja
1
N. H. Ponters, A. P. Dores
1
N. Mdaka
1
NADMO Ghana
1
NASTAD (National Alliance of State & Territorial AIDS Directors)
1
National Agency for the Control of AIDS (NACA), Abuja Nigeria
1
National AIDS Commission of Liberia
1
National AIDS Control Organization (NACO), Ministry of Health and Family Welfare, Government of India
1
National AIDS Control Organization (NACO), United Nations Development Programme (UNDP)
1
National Centre for Disease Control (NCDC)
1
National Child Traumatic Stress Network (NCTSN) & National Center for PTSD
1
National Department of Health, Republic of South Africa
1
National Grassroots and Disabilities Organization (NGDO), National Council for Women with Disabilities (NCDW), Bangladesh Legal Aid and Services Trust (BLAST)
1
National HIV
1
National Human Rights Commission
1
National Institute of Mental Health NIH
1
National Malaria Control Programme (NMCP) Communicable Disease Control Division Directorate General of Health Services Ministry of Health & Family Welfare Bangladesh
1
National Primary Health Care Development Agency
1
National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS), India
1
National TB Control Program, Department of Health
1
National Union of Disabled Persons of Uganda (NUDIPU)
1
National Vector Borne Disease Control Programme (NVBDCP)
1
NCTSN
1
Neuron Review
1
New ERA
1
NFD-N (National federation of the disabled- Nepal)
1
NHSSP
1
Nidhi Singal
1
Niederberger, E.
1
Noel G. Macalalad, Ma. Cecilia G. Ama, Arthur B. Lagos et al.
1
Norad
1
Norwegian Ministry of Foreign Affairs
1
NOVA SCOTIA
1
NRSAD (National Religious Association for Social Development)
1
Nuclear Threat Initiative (NTI) and the Johns Hopkins Center for Health Security (JHU)
1
O. O. Simooyqa
1
Ogden, S., Gallo, K., Davis, S., et al
1
Olivia Tiberi
1
Oosterhoff, P. and Wilkinson, A
1
Organisation mondiale de la Santé
1
Organizaición Mundial de la Salud
1
Osama Abas, Faten Abdelaziem & Ayman Kilany
1
OSF and OSISA the Centre for Human RightsPretoria University Law Press (PULP)
1
Overseas Development Institute (ODI)
1
Ovid
1
Oxfam International
1
O’Connell, Meghan
1
P. Brouwers
1
P. Drain, and T. Hall
1
P. J. de Vries
1
P. Kruger
1
P. Monfiston
1
P. Pipero
1
Pact (Building Capacity Worldwide)
1
Pact Inc. and International Center for Research on Women (ICRW)
1
Paget Stanfield, Martin Brueton, Michael Chan, Michael Parkin, and Tony Waterston
1
PAHO, WHO
1
Pan American Health Organisation PAHO
1
Panko Reis, J.
1
Patel V, Simon G, Chowdhary N, Kaaya S, Araya R
1
PATH
1
Paul, A., Adeloye, D., George-Carey, et al.
1
Peden, Margie et al.
1
People's Health Movement
1
Peoples-uni
1
Peter Elyanu
1
Philippine Heart Association
1
Philippine Society for Microbiology and Infectious Diseases
1
Plan International
1
PMC (US National Library of Medicine National Institutes of Health)
Vaccins antirabiques: Note de synthèse de l’OMS – avril 2018
Weekly epidemiological record / Relevé épidémiologique hebdomadaire
20 APRIL 2018, 93th YEAR / 20 AVRIL 2018, 93e ANNÉE
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.more
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha...rmaceutical products, including product pricing, the regulatory environment and patent status, which together shape the national hepatitis response in different settings. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.more
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ...two to four; and the recommendation for intralesional antimonials is now strong. For mucosal leishmaniasis there is now a strong recommendation for use of pentavalent antimonials with or without oral pentoxifylline. For visceral leishmaniasis, the strong recommendations for use of pentavalent antimonials and amphotericin B deoxycholate are now conditional.more
The World Health Organization (WHO) convened a meeting of the Technical Advisory Group on Buruli ulcer at its headquarters in Geneva, Switzerland on 25 to 27 March 2019
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi...stance in adults, children and adolescents receiving dolutegravir-based ART.
This sentinel method is implemented complementary to WHO-recommended methods for estimating nationally representative levels of acquired HIV drug resistance. more
In support of the London Declaration goals, PATH aims to catalyze engagement of the diagnostics industry and product development efforts. As part of this work, PATH conducted a diagnostic landscape analysis to identify gaps and evaluated current and nascent HAT diagnostics that may provide solutions....
We conducted literature reviews and interviews with key stakeholders to identify use cases for HAT diagnostics, understand current practices, and analyze progress toward more robust diagnostics across
different biomarkers.more
The objectives of the meeting were:
1. To step up the commitment of national authorities and technical and financial partners toWHO’s elimination objective for g-HAT.
2. To share achievements, challenges and views on the elimination goal among countries and implementing partners.
3. To assess t...he status of critical technical aspects to be solved in research and development of drugs and diagnostic tools, epidemiology, vector control and animal reservoirs.
4. To define the mechanisms for strengthening and organizing collaboration and coordination among stakeholders.more
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec
le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les
populations sous TAR. Bien que la résistance au DT...G ne soit pas apparue dans les populations naïves aux TAR incapables
de supprimer la charge virale dans les essais cliniques, certains éléments portent à croire que la résistance au
DTG peut émerger chez les personnes suivant des schémas thérapeutiques incluant le DTG. L’OMS recommande aux
pays qui étendent les TAR incluant le DTG d’accompagner ce déploiement d’une surveillance en routine de la pharmacorésistancemore
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el
mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este
antirretrovírico en las poblaciones tratadas con esquemas que lo conti...enen. Si bien no se ha detectado resistencia
al dolutegravir en los ensayos clínicos con poblaciones no tratadas antes con antirretrovíricos en las que se ha
detectado una viremia persistente pese al tratamiento, los datos indican que puede surgir en quienes toman esquemas
con dolutegravir. La OMS recomienda a los países que estén ampliando el tratamiento con dolutegravir que acompañen
su despliegue con la vigilancia sistemática de la farmacorresistencia.more